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Late-onset sepsis (LOS) is a highly consequential complication of
preterm birth and is defined by a positive blood culture obtained
after 72 h of age. The causative bacteria can be found in patients’
intestinal tracts days before dissemination, and cohort studies sug-
gest reduced LOS risk in breastfed preterm infants through un-
known mechanisms. Reduced concentrations of epidermal growth
factor (EGF) of maternal origin within the intestinal tract of mice
correlated to the translocation of a gut-resident human pathogen
Escherichia coli, which spreads systemically and caused a rapid, fatal
disease in pups. Translocation of Escherichia coliwas associated with
the formation of colonic goblet cell-associated antigen passages
(GAPs), which translocate enteric bacteria across the intestinal epi-
thelium. Thus, maternally derived EGF, and potentially other EGFR
ligands, prevents dissemination of a gut-resident pathogen by inhib-
iting goblet cell-mediated bacterial translocation. Through manipu-
lation of maternally derived EGF and alteration of the earliest gut
defenses, we have developed an animal model of pathogen dissem-
ination which recapitulates gut-origin neonatal LOS.
goblet cells | breast milk | sepsis | neonate | bloodstream infections
Late-onset neonatal sepsis (LOS) can be caused by a variety ofpathogens, occurs at least 72 h after birth, accounts for 26%
of all deaths in preterm infants, and results in an increased risk of
long-term neurocognitive problems (1, 2). LOS has remained an
important challenge in preterm infant care (3) due to the con-
tinuing reduction in the age of viability of very low birth weight
(VLBW, birth weight ≤ 1,500 g) infants, who are at greater risk
for bloodstream infections (BSIs), with an incidence of 10% and
a mortality rate between 30 to 50% (1). Recent clinical data
indicate incidence of LOS may be decreasing, though it remains
unclear which interventions have the most impact in reduction of
neonatal BSIs and LOS (4). Great effort has been devoted to
hygiene related to invasive procedures (5, 6), and there is in-
creasing focus on breastfeeding (7, 8).
In a substantial portion of LOS cases, the causative pathogen
can be found to reside in the gut before it disseminates (9–12). It
is hypothesized that an immature intestinal barrier enables
translocation of such resident gut bacteria, but the mechanisms
allowing or inhibiting translocation of the gut microbiota in early
life remain unknown. These infections occur during the first 60 d
of life, a time in life when exclusive breastfeeding is recom-
mended. Formula-fed preterm infants have greater intestinal
permeability compared to breast milk-fed preterm infants (13),
and in animal models, formula feeding enables bacterial trans-
location from the gut to the mesenteric lymph nodes (MLNs)
and the liver (14–16). Epidermal growth factor (EGF) is a
growth factor that is maternally supplied with high concentra-
tions in colostrum and decreases in concentration in breast milk
throughout lactation (17–19), and reduces bacterial translocation
in formula-fed animals (20).
Here we disrupt EGF receptor (EGFR) signaling in neonatal
mice and use asynchronously cross-fostered pups to reduce high
luminal EGF concentrations originating from maternal milk
perinatally, both of which result in bacterial translocation from
the gut to the mesenteric lymph nodes and spleen. Following
EGFR disruption or asynchronously cross-fostering, mice de-
veloped a rapid fatal response to oral challenge of Escherichia
coli isolated from the bloodstreams of LOS patients, which were
also of gut origin in those neonates. However, other gut-resident
commensal E. coli from infants without disease were not lethal,
despite their ability to translocate in this model. E. coli trans-
location was associated with goblet cell-associated antigen pas-
sages (GAPs) formation by colon goblet cells and inhibited by
luminal EGF via EGFR activation in goblet cells. Thus maternal
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EGF, and potentially other EGFR ligands, inhibits translocation
of a gut-residing pathogen in offspring by directly acting on
goblet cells and inhibiting GAP formation in the offspring’s co-
lon, thereby interdicting gut-resident pathogens from traversing
the epithelium and gaining systemic access.
Results
Infants born preterm and fed mother’s own milk (MOM) have a
reduced risk of LOS (21, 22). EGF is abundant in breast milk
after parturition, decreases throughout lactation, and has been
observed to improve intestinal barrier function and reduce bac-
terial translocation in offspring (20). Therefore, we measured
EGF in the stool of VLBW infants (SI Appendix, Table S1) that
were fed MOM or formula over the first 60 d of life to assess the
contribution of maternal breast milk to luminal EGF concen-
trations. Stools from the breastfed children contained signifi-
cantly greater concentrations of EGF, and this concentration
diminished over time, reflecting the reduction in concentration
in breast milk of EGF (17–19) (Fig. 1A and SI Appendix, Fig.
S1A). Similar temporal trends of EGFR ligands amphiregulin
(AREG), transforming growth factor alpha (TGF-α), and
heparin-binding EGF like growth factor (HB-EGF), which have
been reported to be present in human breast milk (17, 23, 24),
were not observed in the stool. Additionally, there were no dif-
ferences in the fecal concentrations of AREG, TGF-α, and HB-
EGF in the stools of MOM-fed or formula-fed children, which
were overall less abundant than EGF in the stool, particularly in
the first 4 wk of life (SI Appendix, Fig. S1 B–D, compare to Fig.
1A). EGF concentrations in murine milk also diminished over
time, reflecting a gradient that could also be measured in the
stool (SI Appendix, Fig. S2A) and lumen (25) of pups during early
life, a time when neonatal mice immunologically resemble the
preterm human infant gut (26, 27).
We next asked if maternal EGF induces a response in the off-
spring that prevents translocation of gut bacteria via activation of the
EGFR. Pups were colonized with E. coli by oral gavage of 2 × 105
Fig. 1. Inhibition of EGFR results in bacterial translocation of gut-residing E. coli. (A) Concentration of EGF as measured by ELISA from the stool of children
fed mother’s own milk (green squares) or formula (gray circles). In B–F, conventionally reared mice were gavaged with 2 × 105 CFUs of E. coli and injected with
EGFRi on DOL5. (B) CFUs in stool following gavage of 2 × 105 CFUs of E. coli C1nalR (blue) or BSI-AnalR (red) in conventionally reared mice on DOL5. (C) CFUs in
mesenteric lymph node (MLN), spleen, and liver 3 d following gavage of 2 × 105 CFUs of E. coli C1nalR (blue) or BSI-AnalR (red) on DOL5 in conventionally reared
mice injected with tyrphostin AG1478 (EGFRi) or vehicle. (D) Neutrophils in the blood 48 h following gavage of 2 × 105 CFUs of E. coli C1nalR or E. coli BSI-AnalR
and injected with EGFRi as indicated or vehicle. (E) Survival of mice following vehicle or EGFRi injection and gavage of 2 × 105 CFUs of E. coli C1nalR or BSI-AnalR.
(F) Weight of mice following gavage of 2 × 105 CFUs of E. coli BSI-AnalR and injected with EGFRi (black), or vehicle (green). Red dots denote moribund pups.
n = 5 individuals in each group with multiple time points in A. n = 5 mice per group in B–D. n = 15 mice per group from 3 independent litters in E. n = 10 mice
per group in F. Individual data points plotted in B–D with mean and SD plotted per group. Statistics used: Linear regression (A), Mann–Whitney (C), one-way
ANOVA (D), two-way ANOVA (F), Kaplan–Meier (E), *denotes statistical significance, P < 0.05 or less.


















































colony-forming units (CFUs) of E. coli BSI-AnalR, a nalidixic
acid-resistant mutant of an E. coli isolated on day of life 21 from
the bloodstream of an infant born at 28 wk gestation (9) or col-
onized with a nalidixic acid-resistant mutant E. coli C1nalR (SI
Appendix, Table S2), a commensal E. coli isolated from the in-
testinal tract of an infant without a bloodstream infection and
injected intraperitoneally (i.p.) with vehicle or an inhibitor of
EGFR activation, tyrphostin AG1478, on day of life (DOL)5.
Both E. coli strains were found in the stool of the pups for at least
7 d following gavage confirming colonization (Fig. 1B); no nali-
dixic acid-resistant bacteria were found in the stool of the dam or
pups prior to inoculation (SI Appendix, Fig. S2B). E. coli BSI-
AnalR or C1nalR could be found in the stool of all mice 3 d after
gavage, but only the MLNs, spleen, and liver of pups treated with
epidermal growth factor receptor inhibitor (EGFRi) contained E.
coli BSI-AnalR or C1nalR (Fig. 1C). EGFRi-treated mice developed
neutrophilia (Fig. 1D) and died following colonization with E. coli
BSI-AnalR but not C1nalR (Fig. 1E). Illness was characterized by a
lack of weight gain (Fig. 1F), and lethargy. Mice injected i.p. with
BSI-A, but not C1, succumbed rapidly, confirming the virulence of
BSI-A as a pathogen when introduced directly into the body cavity
of mice (SI Appendix, Fig. S3). The mean lethality rate per litter in
EGFRi-treated mice exposed to BSI-A was 75% (SI Appendix,
Fig. S4). Thus, following inhibition of EGFR in pups, E. coli
resident in the gut disseminate and, depending on the microbe,
can cause rapid and significant lethality.
To identify where E. coli translocate following colonization,
small intestine and colon lamina propria, mesenteric lymph
nodes, and spleen were homogenized and plated on MacConkey
agar plates containing nalidixic acid following oral challenge and
EGFRi injection. At 24 h, E. coli BSI-AnalR were largely found in
the lamina propria of the colon, but not small intestine. E. coli
BSI-AnalR was recovered from the MLN after 48 h and from the
spleen and liver after 72 h (Fig. 2A). These data suggest that E.
coli BSI-AnalR translocate via the colon epithelium. Goblet cells,
intestinal epithelial cells of the secretory lineage, have been
observed to be a portal of entry for pathogens (28, 29) and are
present and functional in the neonatal intestinal epithelium
following birth (30). Specifically, colon goblet cells can deliver
antigens and live bacteria from the intestinal lumen to the colon
lamina propria and colon mesenteric lymph node, through the
formation of goblet cell-associated antigen passages (GAPs) (25,
31). Luminal EGF inhibits colon GAP formation in neonates
through EGFR activation specifically on goblet cells (25, 32),
and accordingly GAP formation occurred in the colon of pups
following treatment with EGFRi (Fig. 2B). Using immunohis-
tochemistry and flow cytometry, we observed that fluorescently
labeled E. coli BSI-A associated with cytokeratin (CK)-
18+ goblet cells in the colon of mice following EGFRi treat-
ment but not with intestinal epithelial cells (IECs) of EGFRi-
treated mice or goblet cells of vehicle-treated mice (Fig. 2 C–E).
Live BSI-AnalR could be isolated from fluorescence-activated cell
(FACS)-sorted goblet cells (GCs), but not IECs, of EGFRi-
treated mice (Fig. 2F), confirming that translocation of live E.
coli occurs via GCs and correlates with GAP formation following
EGFRi treatment.
We expanded our testing to additional strains of E. coli isolated
from preterm infants. The nalidixic acid-resistant mutants of E.
coli BSI-C, a bloodstream isolate from a sepsis patient (9), and E.
coli C2, a gut commensal not known to cause disease that was
isolated from the stool of an infant, translocated similarly fol-
lowing colonization and EGFRi administration (Fig. 2G). Only
BSI-AnalR and BSI-CnalR caused morbidity in pups that had been
administered EGFRi (Fig. 2H). Furthermore, three of four other
E. coli bloodstream isolates from sepsis patients were lethal in
pups following EGFRi treatment (Fig. 2I and SI Appendix, Table
S2), suggesting that E. coli from bloodstream infections result in
systemic disease, but commensal E. coli do not, even though they
both disseminate. Initial screen for recognized E. coli virulence
factors using whole genome sequences from BSI-A, BSI-C, C1,
and C2 revealed no common virulence factors present in both of
the pathogenic strains that were not present in at least one of the
nonpathogenic strains. Bloodstream isolates BSI-A and BSI-C and
control isolates C1 and C2 have four, seven, four, and three pu-
tative virulence loci, respectively. Only four loci were shared by
more than one isolate: fliC, which encodes flagellar filaments,
hlyE, which encodes a pore-forming hemolysin, and iss and traT,
which encode proteins that confer resistance to serum comple-
ment (SI Appendix, Table S3).
Deletion of EGFR from goblet cells using an inducible Math1-
driven Cre recombinase resulted in GAP formation on DOL5 in
EGFRf/fMath1PGRCre mice (Fig. 3A). E. coli BSI-AnalR and C1nalR
could be found in the stool of all mice 3 d after gavage indicating
colonization, but only disseminated to the MLN, spleen, and liver of
EGFRf/fMath1PGRCre mice, replicating translocation of bacteria
following EGFR inhibition (Fig. 3B). Again, mice quickly suc-
cumbed following infection with E. coli BSI-AnalR but not C1nalR
following translocation (Fig. 3C). Thus, sensing by EGFR on goblet
cells regulated bacterial translocation across the colon epithelium.
The concentration of EGF in murine milk decreases throughout
lactation (SI Appendix, Fig. S2A). To model the exposure to low
EGF concentrations seen in formula-fed children, we asynchro-
nously cross-fostered mice by housing 1 d old pups with dams that
delivered 10 d earlier (Fig. 4A). Asynchronously cross-fostered
(ACF), but not synchronously cross-fostered (SCF) pups (1 d old
pups cross-fostered to a different dam having delivered a litter on
the same day, Fig. 4A), had reduced concentrations of EGF in
their stool, suggesting that fecal EGF quantities in pups reflect the
EGF concentration in their source of maternal milk (Fig. 4B).
To evaluate if ACF enables bacterial translocation of gut-
resident bacteria and potentiates sepsis, mice were ACF on
DOL1 and colonized with C1nalR or BSI-AnalR on DOL5.
Three days postinfection, E. coli BSI-AnalR and C1nalR were
found in the stool of both SCF and ACF mice indicating all mice
were colonized (Fig. 4C), but were only found in the MLN,
spleen, and liver of ACF mice. This is similar to the results in the
EGFRi-treated mice (Fig. 4D), and supports that ACF results in
bacterial translocation and systemic dissemination. Additionally,
ACF mice quickly succumbed following colonization with E. coli
BSI-AnalR but not C1nalR (Fig. 4E). Both SCF and ACF mice
died equally in response to i.p.-injected E. coli BSI-AnalR, sug-
gesting maternal disruption of EGF in ACF mice specifically
increases risk of sepsis due to enteric pathogens, but not sys-
temically introduced pathogens (SI Appendix, Fig. S5).
E. coli BSI-AnalR was recovered from the colon lamina propria
and, to a significantly lesser extent, the small intestine lamina
propria 24 h after gavage of ACF mice, (Fig. 5A) similar to the
observations in EGFRi-treated mice (Fig. 2A). GAPs formed in the
colons of ACF pups, but not SCF pups, and this formation was
inhibited by luminal EGF (Fig. 5B). Additionally, the epithelium of
ACF pups contained significantly decreased phosphorylated EGFR,
indicating EGFR is less activated in ACF mice. Phosphorylation of
EGFR on the epithelium was restored upon luminal EGF admin-
istration (Fig. 5C) suggesting reduced activation of epithelial
EGFR is consistent with reduced luminal EGF in ACF mice.
Additionally, E. coli BSI-AnalR was found within GCs, but not
IECs, of the ACF mice, and the presence of E. coli BSI-AnalR in
GCs was significantly diminished following EGF administration
(Fig. 5D). To confirm that luminal EGF was sufficient to protect
from gut-origin sepsis in ACF mice, ACF mice were infected with
E. coli BSI-AnalR and gavaged with either a single dose of
recombinant murine EGF at the time of infection, or daily ad-
ministrations of EGF throughout the course of the infection model.
ACF mice given daily EGF had reduced bacterial translocation to
the MLN, spleen, and liver even though colonization was not af-
fected (Fig. 5E). Finally, daily EGF significantly protected ACF mice






































































following BSI-AnalR infection (Fig. 5F). In contrast, daily adminis-
tration of EGF to EGFRi-treated mice or EGFRf/fMath1PGRCre
mice failed to inhibit GAP formation, prevent bacterial trans-
location, or protect from disease (SI Appendix, Fig. S6), indicating
the necessity of EGFR ligands to be actively sensed by the off-
spring to provide protection from translocating bacteria. Taken
together, these data suggest disruption of maternally derived
EGF, and potentially other EGFR ligands, reduces EGFR acti-
vation, GAP formation by GCs, and bacterial translocation via
colon GAPs. Additionally, we found dissemination of pathogenic
E. coli but not commensal E. coli resulted in a fatal sepsis-like
disease in pups following EGFR ligand or EGFR disruption.
Discussion
The many postulated beneficial effects of breast milk, particu-
larly MOM, include reducing intestinal permeability (13) and
preventing bacterial translocation (14–16). These effects plausi-
bly contribute to the partial reduction of the risk of LOS among
breastfed preterm infants (21, 22). EGF and other EGFR li-
gands, components of breast milk, can contribute to each of
these functions through direct ligation of the EGFR on goblet
cells in the colon of offspring. Breast milk contains EGF and
other EGFR ligands, such as AREG, TGF-α, and HB-EGF (17,
23, 24), though at reduced concentrations compared to EGF (18,
19). We found no significant difference in the concentration of
AREG, TGF-α, and HB-EGF in the stool between MOM-fed and
formula-fed children, suggesting maternally derived EGF is the
predominant EGFR ligand biologically available throughout the
entirety of the GI tract, including the lower large intestine. We
recognize that other EGFR ligands may also be affected following
ACF and EGFR inhibition and that in some systems EGFR ligands
can have complementary and overlapping roles (33). However, the
Fig. 2. Translocation of E. coli is associated with colon GAP formation. Conventionally reared mice were gavaged with 2 × 105 CFUs of E. coli and injected
intraperitoneally with EGFRi on DOL5. (A) CFUs per organ (small intestine lamina propria [SI LP], colon lamina propria [Colon LP], mesenteric lymph node [MLN],
and spleen), following gavage of 2 × 105 CFUs of BSI-ANalR in EGFRi-treated mice. (B) GAPs per colon crypt in conventionally reared mice treated with EGFRi or
vehicle. (C) Immunohistochemistry image of colon epithelium from a vehicle (PBS, Left) or EGFRi-treated (Right) mouse following gavage of CFSE-labeled E. coli
BSI-A (green) stained with CK-18 (red), and DAPI (blue), Inset of single CK-18+ goblet cell containing E. coli. (Scale bar: 10 μm.) (D) Gating strategy for colon CD45−
epithelial cells showing UEAI+CK18+ goblet cells (GCs) and UEA-I−CK18− intestinal epithelial cells (IECs) containing Vybrant RubyRed-labeled E. coli BSI-A. (E)
Percentage of GCs or IECs containing E. coli BSI-A. (F) CFUs of BSI-AnalR in IECs and GCs FACS-sorted based on the gating strategy in D. (G) CFUs in stool, mesenteric
lymph node (MLN), spleen, and liver 3 d following gavage of 2 × 105 CFUs of E. coli C1nalR, 2nalR, BSI-AnalR, BSI-CnalR in EGFRi-treated mice. (H) Survival of EGFRi-
treated mice following gavage of 2 × 105 CFUs of E. coli strains. Dotted lines denote commensal strains, not known to cause disease; solid lines denote E. coli
isolated from patient’s bloodstream (SI Appendix, Table S2). (I) Survival of EGFRi-treated mice following gavage of 2 × 105 CFUs of E. coli strains isolated from
patient’s bloodstream (SI Appendix, Table S2). n = 5 mice per group in A and G. n = 3 mice per group in B, E, and F. Representative image and flow plots of three
independent mice shown in C and D. n = 5 mice per group in H. Individual data points plotted in A, B, and E–G with mean and SD plotted per group. Statistics
used: Mann–Whitney (B), one-way ANOVA (E and F), Kaplan–Meier (H), *denotes statistical significance, P < 0.05 or less.


















































relatively higher levels of EGF in breastmilk, and the ability of
enteral recombinant EGF in mice to restore the intestinal barrier
function, prevent bacterial translocation, and avert disseminated
bacterial infection after enteral challenge with a pathogenic E. coli
strongly suggest that EGF is a protective element in maternal milk.
Other breast milk constituents might confer protection from
enteric pathogens including maternal immunoglobulin A (IgA)
(34, 35) and oligosaccharides (36), both of which are also found
in higher concentrations in breast milk soon after parturition
compared to later in lactation and may also be disrupted by
ACF. The individual contributions of these maternal factors can
be explored in the ACF model as IgA may contribute to pro-
tection from invasive enteric pathogens through directly binding
and preventing adherence and evasion (37, 38), and oligosac-
charides support the maturation of the normal infant microbiota
that may provide colonization resistance (39, 40).
Other models of enteric infections have demonstrated invasive
organisms associate with goblet cells (28, 41). We extend this
finding to GAP formation by goblet cells in the colon consistent
with our previous work showing bacterial translocation through
the colon occurs when bacteria pass transcellularly through
goblet cells when forming GAPs (31). EGFR activation inhibits
Fig. 4. Asynchronous cross-fostering results in translocation of gut-residing E. coli. (A) Schematic of asynchronous cross-fostering (ACF) protocol. (B) Con-
centration of EGF in stool of conventionally reared (Con, black triangle), SCF (green circles), or ACF (blue squares) pups. (C) CFUs in stool 3 d following gavage
of 2 × 105 CFUs of E. coli C1nalR (blue) or BSI-AnalR (red) in SCF and ACF mice. (D) CFUs in mesenteric lymph node (MLN), spleen, and liver 3 d following gavage
of 2 × 105 CFUs of E. coli C1nalR (blue) or BSI-AnalR (red) in SCF and ACF mice. (E) Survival of SCF and ACF mice following gavage of 2 × 105 CFUs of E. coli C1nalR or
BSI-AnalR in SCF and ACF mice. n = 5 in B–D. n = 15 mice from three independent litters per group. Individual data points plotted in B–Dwith mean and SD plotted
per group. Statistics used: two-way ANOVA (B), Mann–Whitney (D), Kaplan–Meier (E), *denotes statistical significance, P < 0.05 or less.
Fig. 3. Goblet cell expression of EGFR is necessary for EGF-driven prevention of bacterial translocation. (A) Counts of GAPs per colon crypt in EGFRf/fMath1PGRCre or
EGFRfl/fl littermates. (B) CFUs in stool, mesenteric lymph node (MLN), spleen, and liver 3 d after gavage of 2 × 105 CFUs of E. coli BSI-AnalR in conventionally reared
EGFRf/fMath1PGRCre or EGFRfl/fl littermates. (C) Survival of EGFRf/fMath1PGRCre or EGFRfl/fl littermates following gavage of 2 × 105 CFUs of E. coli BSI-AnalR. n = 6 mice per
group in A–C. Individual data points plotted in A and B with mean and SD plotted per group. Statistics used: Mann–Whitney (A and B) Kaplan–Meier (C), *denotes
statistical significance.






































































GAP formation in early life (25), suggesting a role for maternally
derived EGFR ligands is to limit bacterial translocation and
protect the offspring from potentially invasive enteric pathogens.
EGF did not appear to have an effect on bacterial habitation in
the lumen, as all pups were colonized similarly by evidence of E.
coli measured in stool. Rather we find direct sensing of EGFR
ligands by the EGFR on goblet cells in the colon of the offspring
provides protection from bacterial translocation and blood-
stream infection. The recent initiative to provide neonatal in-
tensive care unit (NICU) patients with human milk through
donor milk banks when MOM is unavailable is a laudable en-
deavor to replace formula with a more complete diet offering
nutrition and protection to the neonate. However, our work
raises the possibility that human milk from donors close to
parturition may offer superior protection compared to human
milk expressed later in lactation, due to temporal availability of
bioactive factors present in human milk.
While all E. coli strains spread systemically, only those isolated
from the bloodstream of LOS cases resulted in noticeable dis-
ease or death in the pups, despite similar translocation and
bacterial load in extraintestinal tissue. We have previously shown
gut-resident commensal bacteria translocating via GAPs circu-
late systemically without causing overt disease (31). Combined
with the previous observation, the variation among E. coli iso-
lates from LOS cases seen in this set of experiments suggest
specific bacterial factors determine virulence following trans-
location from the intestine. Initial screens for virulence loci
found no common factors present in both of the pathogenic
strains that were not present in at least one of the nonpathogenic
strains. Our identification of several virulence loci in the
bloodstream isolates and in the controls is potentially interesting,
but the assignment of a virulence locus in E. coli obligates large
specimen sets from cases and controls and extensive in vitro and
in vivo experimental data to infer mechanisms. There are many
studies of extraintestinal pathogenic E. coli virulence loci, but
bloodstream isolates from infants are underrepresented in these
analyses. The association between strains and outcomes should be
considered to be provisional, as one of five bloodstream isolates
did not cause disease in mice. An intensive survey of pathogenicity
of neonatal wild-type E. coli would be informative. Also, even
though this study is limited to E. coli organisms, LOS can be
caused by multiple different genera, including Enterococci, Strep-
tococci, and other Enterobacteriaceae species (3). Though the
generalizability of GAP translocation as a portal of entry of spe-
cific pathogens is not established by our data, we have previously
shown both Gram-negative and Gram-positive bacteria can
translocate via GAPs (31). Further work will determine the variety
of bacteria that can utilize goblet cells to translocate in early life
following EGFR disruption and should pursue additional and
potentially complementary mechanisms, such as toll-like receptor
(TLR) activation in the gut mucosa. Compared to models of
neonatal sepsis utilizing i.p. injection of lipopolysaccharide (LPS),
or cecal contents, ACF more faithfully recapitulates the enteric
route of entry that has been associated with late-onset sepsis cases
(9–12, 42). Combining the previous studies with the observation
that the enteric route of entry has been shown to contribute to
virulence and disease when compared to i.p. injection (43), ACF
represents a physiologic route for bacterial translocation. ACF
and colonization offer a minimally invasive model of dissemina-
tion without pharmacological manipulation or physical breach of
the intestinal or skin barriers.
In summary, our model of enterally acquired bloodstream
infections following translocation of a gut-residing pathogen
demonstrates that maternally derived EGF, and potentially other
EGFR ligands, can prevent this process. GAPs, which formed in
response to decreased or disrupted EGFR signaling, were
exploited by enteric bacteria. Depending on the bacteria, trans-
location resulted in the rapid sepsis-like death of offspring in this
model of LOS. This model has profound relevance and appli-
cation to the study of LOS and the development of therapies for
the prevention and treatment of LOS unique to the neonatal
phase of life.
Fig. 5. Luminal EGF protects against bacterial translocation and susceptibility to bloodstream infections. (A) CFUs in lamina propria of small intestine or colon
following gavage of 2 × 105 CFUs of E. coli BSI-AnalR in ACF mice. (B) Counts of GAPs per colon crypt in SCF or ACF mice and gavaged with EGF (10 ng/mL) or
vehicle. (C) Concentration of phosphorylated EGFR per colon epithelial fraction as measured by ELISA. GAPs (black), ACF given a single gavage of recombinant
murine EGF at the time of infection (red), or ACF mice given daily gavages of EGF (green). (D) Percentage of GCs or IECs containing E. coli BSI-AnalR. (E) CFUs in
stool, mesenteric lymph node (MLN), spleen, and liver in the days following gavage of 2 × 105 CFUs of E. coli BSI-AnalR in ACF mice treated with EGF. (F)
Survival of ACF mice following gavage of 2 × 105 CFUs of E. coli BSI-AnalR in ACF mice (black), ACF gavaged with EGF (10 ng/mL) at the time of infection (red),
or ACF mice given daily gavages of EGF (10 ng/mL) (green). n = 4 mice in A, n = 4 mice in B–D. n = 5 in E. n = 6 mice per group in F. Individual data points
plotted in A–Ewith mean and SD plotted per group. Statistics used: one-way ANOVA (A–E), Kaplan–Meier (F), *denotes statistical significance, P < 0.05 or less.



















































Mice. All mice were bred for 10 or more generations on the C57BL/6 back-
ground. Math1PGRCre mice (44) were purchased from The Jackson Laboratory
and bred and maintained in-house. EGFRf/f mice (45) were a gift of Dr. David
Threadgill, University of North Carolina, Chapel Hill, NC. To genetically de-
plete EGFR in GCs, mice were bred to generate EGFRf/fMath1PGRCre and
EGFRf/f littermates. These mice were injected i.p. with mifepristone (Caymen
Chemical Company) (10 mg/kg), which was dissolved at a concentration of
2 mg/mL in sunflower oil, on DOL2, 4, and 6. Cohoused littermates were
used when possible as experimental groups and controls to minimize dif-
ferences in the gut microbiota. Animal procedures and protocols were
performed in accordance with the Institutional Animal Care and Use Com-
mittee at Washington University School of Medicine. In some experiments,
mice were injected i.p. with 500 μg/kg tyrphostin AG1478 (EGFRi) (Sigma
Aldrich) on DOL5 to inhibit EGFR activation. EGFRi was initially diluted in
dimethyl sulfoxide (DMSO) to a concentration of 3.3 mg/mL, then further
diluted in phosphate buffered saline (PBS) to a concentration of 33 μg/mL.
Mice were injected with 16.6 μL, per gram bodyweight on DOL5 (25). In
some experiments, mice were gavaged with 100 ng recombinant EGF (She-
nandoah) in 50 μL PBS. Only litters from naïve mothers not previously ex-
posed to E. coli isolates were used for experiments.
Human Studies. Bloodstream and fecal isolates of E. coli, and infant stools,
were obtained from a prospective case-cohort study of the role of gut mi-
crobial populations in necrotizing enterocolitis in infants hospitalized in the
NICUs at St. Louis Children’s Hospital and the Children’s Hospital of Okla-
homa University, and a study of the postdischarge microbiome in infants
who had been hospitalized at St. Louis Children’s Hospital. Both site’s in-
stitutional review board approved this study; written informed consent was
obtained from parents before enrollment. Details of the cohorts and
methodology of stool collection are provided in the SI Appendix. Some of
the E. coli strains used in this study have been previously published (9, 46).
Pathogenic E. coli (E. coli BSI-A, BSI-B, BSI-C, BSI-D, BSI-E, BSI-F, SI Appendix,
Table S2) were isolated from the bloodstream of NICU patients. Strains BSI-A
and BSI-C were also identified in the patient’s stool prior to onset of clinical de-
terioration and positive blood culture diagnosing LOS (9), and we did not seek
cognate E. coli in the stools from the other patients from whom we isolated
bloodstream E. coli. Commensal E. coli species (E. coli, C1, C2, SI Appendix, Table
S2) were isolated from the stool of discharged pediatric patients, and not known
to cause disease. DNA was isolated from single colonies and sequenced following
PCR amplification of the adk, fumC, gyrB, icd, mdh, purA, and recA genes for
multilocus sequence type (MLST) identification (Genewiz) (SI Appendix, Table S2).
Full genome sequences of BSI-A (9), BSI-C (9), C1 (46), and C2 (47) are publicly
available. PRJNA/GenBank/Sequence Read Archive (SRA) run accession nos.
BSI-A (ST69): 203059/ATNW00000000/SRR769039 and BSI-C (ST70): 203060/
ATNV00000000/SRR769057; C1 (ST35): accession no. GCA_008081795.1; C2:
PRJNA602838/SAMN13909231/JAADAA000000000.
Virulence Factor Screen. Primers for extraintestinal pathogenic (ExPEC) viru-
lence factors were retrieved from the literature and used for in silico PCR
with the command line tool primer search from EMBOSS (48). Only assem-
blies with matches for both primers for each gene were reported. In addi-
tion, assemblies were analyzed against the VirulenceFinder database and
hits against ExPEC virulence genes are reported (49).
Stool Samples. Frozen stool previously collected was identified from patients
1) having either an exclusive human milk (MOM) or formula-fed diet during
the first 60 d of life, 2) negative for necrotizing enterocolitis or sepsis, and 3)
having at least 10 stool specimens available from birth through day of life 60.
Five breastfed patients and five formula-fed patients were included in this
study, with at least 10 time points per individual between DOL0 and DOL60.
Patient metadata are available in SI Appendix, Table S1.
Quantification of EGFR Ligands from Stool. Frozen stool specimens were
resuspended in PBS, homogenized, and analyzed by enzyme-linked immuno-
sorbent assay (ELISA) for human EGF (R&D Systems), human amphiregulin
(AREG) (R&D Systems), human TGF-α (R&D Systems), and human heparin-
binding EGF (HB-EGF) (R&D Systems), per the manufacturer’s protocol. For
mice, stool was collected in PBS, homogenized, and analyzed by ELISA for
murine EGF (R&D Systems), per manufacturer’s protocol.
Asynchronous Cross-Fostering. At first sign of pregnancy, male breeders were
removed from the cages of female breeders. On DOL1, pups were placed in a
new cage with a dam that had delivered pups 10 d prior and was still actively
nursing (asynchronous cross-fostering, ACF), or a dam that had delivered pups
on the same birthdate as pups (synchronous cross-fostering SCF). All pups,
bedding, and dam’s nostrils were wiped with imitation vanillin extract to
increase litter acceptance by dam. Mice were monitored for litter acceptance
and maternal care, and weighed daily.
E. coli Infection. On DOL5, mice were gavaged with 20 μL PBS containing
107 CFUs/mL (equivalent to 2 × 105 CFU) E. coli. Stool was collected to
monitor colonization. Mice were monitored for disease, including lack of
weight gain, lethargy, pallor, lack of nursing, and death. In some experi-
ments, moribund mice were euthanized to confirm translocation of enteric
bacteria to extraintestinal organs and compare the MLST of recovered col-
onies to those of the challenge E. coli. Moribund was recognized as lethargic
pups excluded from the nest that remained motionless when weighed on scale
and failed to gain weight. In survival experiments, mice were monitored twice
daily for signs of disease and lack of weight gain. In some mice, 24 h following
gavage, small intestine and colon lamina propria were isolated to analyze
bacterial translocation. In some mice, 3 d following gavage, spleen, MLN, and
liver were isolated to analyze bacterial translocation. Litters of four or more
were all colonized with the same E. coli strain to avoid cross-contamination
and repeated at least three times to control for litter variability. In EGFRi
experiments, litters of eight or more were all colonized with the same
E. coli strain and then injected with EGFRi or PBS within the same litter
to control for litter variability. EGFRf/fMath1PGRCre and EGFRf/f littermates
within a single litter were all colonized with the same E. coli strain and
treated with mifepristone.
Nalidixic Acid-Resistant E. coli Strains. E. coli strains BSI-A, BSI-C, C1, and C2
were grown in 10 mL Luria-Bertani (LB) broth containing 4 μg/mL nalidixic
acid (Acros Organics, Thermo Fisher Scientific). Isolates were plated on
MacConkey agar plates containing 4 μg/mL nalidixic acid. The process was
repeated using increasing amounts of nalidixic acid until E. coli strains grew in
media containing 20 μg/mL nalidixic acid, and the MLST types were con-
firmed to remain unchanged. In all experiments, E. coli was grown by in-
oculating 10 mL of LB containing 4 μg/mL nalidixic acid with a frozen chip of
E. coli glycerol stock (stock made from 109 CFUs in 1.5 mL PBS:glycerol in a
1:1 ratio). Cultures were grown shaking, at a 45° slant, at 37 °C to an optical
density (OD) of 0.30 for a concentration of 108 CFUs/mL. Cultures were
pelleted, washed in PBS, and resuspended to a concentration of 107 CFUs/mL
in PBS for further use.
Blood Collection and Flow Cytometry.On DOL5, mice were gavaged with 20 μL
PBS containing 106 CFUs of E. coli and injected i.p. with EGFRi or vehicle.
Forty-eight hours following gavage, whole blood was collected via cheek
bleed. Two drops (10 μL) were collected directly into a microcentrifuge tube
containing 90 μL of 50 mM ethylenediaminetetraacetic acid (EDTA). Neu-
trophils in blood were identified as CD45+ (monoclonal antibody 30-F11,
eBioscience, Thermo Fisher Scientific) Ly6G/Ly6C+ (monoclonal antibody RB6-
8C5, eBioscience). Flow cytometry was collected and analyzed on an Attune
NxT flow cytometer (Invitrogen).
Bacterial Quantification in Organs and Stool. Small intestines or colons were
harvested, rinsed with PBS, and Peyer’s patches or colonic patches were re-
moved and discarded. Epithelial cell populations were released by incubating
the intestines for 15 min in a 37 °C rotating incubator in 20 mL Hank’s balanced
salt solution (HBSS) media (BioWhittaker) containing 5 mM EDTA and genta-
micin (50 μg/mL) as previously described (50). Following removal of epithelium,
isolated lamina propria was cut into pieces. We recovered splenic, MLN, and
lamina propria cells as previously described (50). Lamina propria pieces, spleen,
MLN, liver, or stool were homogenized in 500 μL PBS with 200 mg 0.1 mm
diameter zirconium silica beads (BioSpec), and homogenized Bullet Blender
Tissue Homogenizer (Next Advance) vortexed on bead beater. Supernatant was
plated on MacConkey agar containing 20 ng/mL nalidixic acid to identify nali-
dixic acid-resistant E. coli, and identity of E. coli strain was confirmed through
MLST identification.
Extraction of Milk from Lactating Dams. Milk was extracted from lactating
dams every third day beginning on postpartum day 5 as described (51).
GAP Quantification, Goblet Cell Staining, and Bacteria Visualization. With mice
under anesthesia, tetramethylrodamine-labeled dextran 10,000 molecular
weight (MW) (10 mg/mL) (Thermo Fisher Scientific) was injected intra-
luminally into the colon. Thirty minutes later, colons were removed and
fixed in 10% buffered formalin for 30 min before blocking in optimal






































































cutting temperature (OCT) compound and freezing as previously de-
scribed (32, 52). Sections were cut and counterstained with DAPI. The
number of GAPs per colon crypt was quantified by immunofluorescence
microscopy as previously described (32, 52). Specimens were blinded for
analysis, and GAPs were identified as dextran-filled columns measuring
∼20 μm (height) × 5 μm (diameter) traversing the epithelium and containing
a DAPI+ nucleus. Colon GAPs were enumerated within the crypts as GAPs
per crypt, which were identified as a ring of DAPI+ epithelial nuclei. Images
were analyzed by fluorescent wide-field microscopy that was performed
with an Axioskop 2 microscope using Axiovision software (Carl Zeiss). In
some experiments, 106 CFUs of E. coli BSI-A were labeled with carboxy-
fluorescein succinimidyl ester (CFSE) as per the manufacturer’s directions
(CellTrace CFSE, Thermo Fisher Scientific) and resuspended into a concen-
tration of 106 CFUs/mL. One hundred microliters (105 CFUs) was intrarectally
administered into the colon. Three hours later, colons were removed and
fixed in 10% buffered formalin for 15 min before blocking in OCT and
freezing as previously described (32, 52). Sections were cut and stained with
CK-18 (Abcam) and DAPI. Immunohistochemistry was performed as pre-
viously described (52).
Flow Cytometry and Sorting of Goblet Cells. CFUs (106) E. coli BSI-A were la-
beled with Vybrant RubyRed (Thermo Fisher Scientific) per the manufac-
turer’s directions and resuspended into a concentration of 106 CFUs/mL. CFUs
(105; 100 μL) were intrarectally administered into the colon. Three hours
later, colons were removed and the epithelial cells were isolated by shaking
tissue in 20 mL of HBSS+5 mM EDTA with gentamicin (50 μg/mL) to kill
extracellular bacteria. Goblet cells were identified as CK-18-fluorescein
isothiocyanate (FITC)+ CD45-allophycocyanin (APC)lo while IECs were iden-
tified as CK-18-FITC− CD45-APC− (CK-18 antibody, monoclonal C-04, Abcam;
CD45 antibody, monoclonal 30-F11, Thermo Fisher Scientific). Cells were ei-
ther analyzed by flow cytometry on an Attune nxT (Invitrogen) or FACS
isolated on a Synergy (Sony) sorter. FACS-isolated cells were homogenized
and plated on MacConkey agar containing 20 ng/mL of nalidixic acid.
Statistical Analysis. Data analysis using Kaplan–Meier survival, one-way
ANOVA (nonparametric Kruskal–Wallis), two-way ANOVA (repeated mea-
sure two-way ANOVA), linear regression analysis, or Mann–Whitney U test
was performed using GraphPad Prism (GraphPad Software Inc.).
Data Availability. Whole genome sequences for BSI-A, BSI-C, C1, and C2 are
publicly available: Bioproject accession PRJNA/GenBank/SRA run accession
nos. BSI-A (ST69): 203059/ATNW00000000/SRR769039 and BSI-C (ST70):
203060/ATNV00000000/SRR769057; C1 (ST35): accession no. GCA_008081795.1;
C2: PRJNA602838/SAMN13909231/JAADAA000000000. All materials, data, and
associated protocols are available upon request from the corresponding
author, K.A.K.
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